NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.


Which medication is not recommended in naive patients if HIV RNA >500,000, known HBV confection, or HIV genotypic testing not available?

  1. Triumeq: Dolutegravir/abacavir/lamivudine

  2. Dovato: Dolutegravir/lamivudine

  3. Biktarvy: Bictegravir/Emtricitabine/TAF

  4. Tivicay + Descovy: Dolutegravir + Emtricitabine/TAF

The correct answer is: Dovato: Dolutegravir/lamivudine

Based on the information provided, Dovato (dolutegravir/lamivudine) is not recommended in naive patients if they have high levels of HIV RNA (>500,000), known hepatitis B virus (HBV) infection, or if HIV genotypic testing is not available. This is because these factors may increase the risk of treatment failure with Dovato. The other options, Triumeq, Biktarvy, and Tivicay + Descovy, may be more suitable for these patients as they contain different combinations of antiretroviral drugs and may be better tolerated in specific patient populations. It is important to consult with a healthcare provider to determine the best treatment option for each individual patient, taking into consideration their medical history, viral load, and availability of HIV genotypic testing.